Metabolic Syndrome in Type 1 Diabetes
- 1 August 2005
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (8), 2019-2024
- https://doi.org/10.2337/diacare.28.8.2019
Abstract
OBJECTIVE—The aim of this study was to estimate the prevalence of the metabolic syndrome in Finnish type 1 diabetic patients and to assess whether it is associated with diabetic nephropathy or poor glycemic control. RESEARCH DESIGN AND METHODS—In all, 2,415 type 1 diabetic patients (51% men, mean age 37 years, duration of diabetes 22 years) participating in the nationwide, multicenter Finnish Diabetic Nephropathy (FinnDiane) study were included. Metabolic syndrome was defined according to the National Cholesterol Education Program diagnostic criteria. Patients were classified as having normal albumin excretion rate (AER) (n = 1,261), microalbuminuria (n = 326), macroalbuminuria (n = 383), or end-stage renal disease (ESRD) (n = 164). Glycemic control was classified as good (HbA1c 9.0%). Creatinine clearance was estimated with the Cockcroft-Gault formula. RESULTS—The overall prevalence of metabolic syndrome was 38% in men and 40% in women. The prevalence was 28% in those with normal AER, 44% in microalbuminuric patients, 62% in macroalbuminuric patients, and 68% in patients with ESRD (P < 0.001). Patients with metabolic syndrome had a 3.75-fold odds ratio for diabetic nephropathy (95% CI 2.89–4.85), and all of the separate components of the syndrome were independently associated with diabetic nephropathy. The prevalence of metabolic syndrome was 31% in patients with good glycemic control, 36% in patients with intermediate glycemic control, and 51% in patients with poor glycemic control (P < 0.001). Similarly, metabolic syndrome increased with worsening creatinine clearance. CONCLUSIONS—The metabolic syndrome is a frequent finding in type 1 diabetes and increases with advanced diabetic nephropathy and worse glycemic control.Keywords
This publication has 36 references indexed in Scilit:
- Factors associated with plasma lipids and lipoproteins in Type 1 diabetes mellitus: the EURODIAB IDDM Complications StudyDiabetic Medicine, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Multiple lipoprotein abnormalities in type I diabetic patients with renal diseaseDiabetes, 1996
- Insulin resistance in insulin-dependent diabetic patients with microalbuminuriaThe Lancet, 1993
- Glucose toxicityEndocrine Reviews, 1992
- Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1989
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988
- Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in FinlandDiabetes Care, 1979
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- Insulin sensitivity and vascular disease in insulin-dependent diabetics.BMJ, 1968